Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study.

Abstract

OBJECTIVE:

To determine the safety and efficacy of glycopyrrolate in the treatment of developmentally disabled children with sialorrhea.

DESIGN:

Placebo-controlled, double-blind, crossover dose-ranging study.

SETTING:

Outpatient facilities in 2 pediatric hospitals.

PATIENTS:

Thirty-nine children with both developmental disabilities and excessive and bothersome sialorrhea.

MAIN OUTCOME MEASURES:

Parent and investigator evaluation of change in sialorrhea and adverse effects.

RESULTS:

Glycopyrrolate in doses of 0.10 mg/kg per dose is effective at controlling sialorrhea. Even at low doses, 20% of children may exhibit adverse effects severe enough to require discontinuation.

CONCLUSIONS:

Glycopyrrolate is effective in the control of excessive sialorrhea in children with developmental disabilities. Approximately 20% of children given glycopyrrolate may experience substantial adverse effects, enough to require discontinuation of medication. Arch Pediatr Adolesc Med. 2000;154:1214-1218.

• Authors: R J Mier, S J Bachrach, R C Lakin, T Barker, J Childs, M Moran
• Journal: Archives of pediatrics & adolescent medicine (Arch Pediatr Adolesc Med) Vol. 154 Issue 12 Pg. 1214-8 (Dec 2000) ISSN: 1072-4710 [Print] United States
• PMID: 11115305 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Muscarinic Antagonists
• Glycopyrrolate

Topics

• Adolescent
• Adult
• Child
• Child, Preschool
• Cross-Over Studies
• Developmental Disabilities (complications)
• Dose-Response Relationship, Drug
• Double-Blind Method
• Glycopyrrolate (adverse effects, therapeutic use)
• Humans
• Muscarinic Antagonists (adverse effects, therapeutic use)
• Sialorrhea (complications, drug therapy)